Variable | Malaria | Number new episodes | Crude incidence rate ratio | P value | 95 % CI | |
---|---|---|---|---|---|---|
No | Yes | |||||
Age | ||||||
0.5–1 years | 31 | 37 | 65 | Reference | – | – |
>1–5 years | 121 | 123 | 272 | 0.85 | 0.397 | 0.590–1.233 |
>5–9 years | 64 | 46 | 77 | 0.57 | 0.013* | 0.371–0.887 |
Blood group | ||||||
A+ | 56 | 41 | 77 | Reference | – | – |
B+ | 73 | 57 | 109 | 1.06 | 0.768 | 0.713–1.581 |
O+ | 78 | 87 | 184 | 1.38 | 0.086 | 0.955–2.000 |
AB+ | 10 | 17 | 36 | 1.66 | 0.091 | 0.922–2.997 |
O− | 1 | 1 | 4 | 2.49 | 0.306 | 0.433–14.340 |
B− | 0 | 1 | 1 | 1.24 | 0.878 | 0.074–20.906 |
AB− | 0 | 1 | 1 | 1.24 | 0.878 | 0.074–20.906 |
Sickle cell genotype | ||||||
Wild type | 158 | 145 | 289 | Reference | ||
Heterozygous | 64 | 46 | 110 | 0.78 | 0.394 | 0.755–1.427 |
Malaria history | 201 | 199 | 412 | 7.33 | 0.008* | 1.674–32.104 |
Reported anti-malarial drug use | 206 | 197 | 386 | 1.68 | 0.247 | 0.698–4.043 |
Reported ITN use | 184 | 189 | 377 | 2.69 | 0.001* | 1.522–4.752 |